油乳剂对伊立替康诱导的小鼠迟发性腹泻的治疗作用
Therapeutic Effect of Oil Emulsion in Mice with Irinotecan-Induced Delayed Diarrhea.
作者信息
Lai Zixuan, Zhang Yong, Hu Xiaoxia, Chen Li, Huang Weimu, Wang Juan, Chen Baoyi, Ren Mihong, Yang Bowen, Su Ziren, Chen Jiannan, Xie Jianhui, Lai Zhengquan, Xie Youliang
机构信息
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, People's Republic of China.
Dongguan Institute of Guangzhou University of Chinese Medicine, Dongguan, 523808, People's Republic of China.
出版信息
Drug Des Devel Ther. 2025 Jun 24;19:5329-5347. doi: 10.2147/DDDT.S517973. eCollection 2025.
BACKGROUND
Chemotherapy-induced diarrhea (CID), particularly delayed diarrhea, often limits clinical use. oil emulsion (BJOE), an adjuvant chemotherapy agent, has been shown to reduce irinotecan-related gastrointestinal side effects. However, its underlying molecular mechanism remains unclear. The cGAS-STING pathway, composed of the cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) and the adaptor protein stimulator of interferon genes (STING), plays an essential role in delayed diarrhea. This work aimed to investigate the therapeutic potential and underlying mechanism of BJOE on irinotecan-induced delayed diarrhea.
METHODS
Gas chromatography-mass spectrometry (GC-MS) was employed to explore the components of BJOE. Macro-observation, histology, PCR, immunohistochemistry, and Western blotting were performed to illuminate the potential mechanism of BJOE on irinotecan-induced delayed diarrhea mice model.
RESULTS
GC-MS analysis identified linoleic acid (20.67%) as BJOE's main component. BJOE effectively mitigated irinotecan-induced delayed diarrhea in mice, as characterized by attenuation of weight loss, colon shortening, hematochezia, and histopathologic damage. It significantly inhibited the mRNA expression levels of inflammatory mediators TNF-α, IL-1β, IL-6, and iNOS, and upregulated barrier gene expression (ZO-1 and occludin). Furthermore, BJOE markedly enhanced mucin production, and increased PCNA protein expression. Concurrently, BJOE remarkably down-regulated the colonic mRNA levels of cGAS, STING, CXCL10, CCL5, and IFN-β. Activation of the cGAS-STING pathway with agonist DMXAA significantly reduced BJOE's therapeutic, anti-inflammatory, and barrier-protective effects. Similarly, stimulating STING substantially reversed BJOE's inhibition on cGAS-STING pathway.
CONCLUSION
BJOE effectively mitigated inflammation and preserved intestinal barrier function, at least partially, via inhibiting cGAS-STING pathway in irinotecan-induced delayed diarrhea. Active components, long-term safety and pharmacokinetics studies were warranted to facilitate translational application.
背景
化疗引起的腹泻(CID),尤其是迟发性腹泻,常常限制其临床应用。榄香烯乳剂(BJOE)作为一种辅助化疗药物,已被证明可减轻伊立替康相关的胃肠道副作用。然而,其潜在的分子机制仍不清楚。由胞质DNA传感器环磷酸鸟苷-腺苷酸合成酶(cGAS)和衔接蛋白干扰素基因刺激物(STING)组成的cGAS-STING通路在迟发性腹泻中起重要作用。本研究旨在探讨BJOE对伊立替康所致迟发性腹泻的治疗潜力及其潜在机制。
方法
采用气相色谱-质谱联用(GC-MS)技术探究BJOE的成分。运用大体观察、组织学、聚合酶链反应(PCR)、免疫组织化学及蛋白质免疫印迹法阐明BJOE对伊立替康诱导的迟发性腹泻小鼠模型的潜在作用机制。
结果
GC-MS分析确定亚油酸(20.67%)为BJOE的主要成分。BJOE有效减轻了伊立替康诱导的小鼠迟发性腹泻,表现为体重减轻、结肠缩短、便血及组织病理学损伤减轻。它显著抑制炎症介质肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和诱导型一氧化氮合酶(iNOS)的mRNA表达水平,并上调屏障基因(紧密连接蛋白1(ZO-1)和闭合蛋白)的表达。此外,BJOE显著增强粘蛋白生成,并增加增殖细胞核抗原(PCNA)蛋白表达。同时,BJOE显著下调结肠中cGAS、STING、CXC趋化因子配体10(CXCL10)、C-C趋化因子配体5(CCL5)和干扰素-β(IFN-β)的mRNA水平。用激动剂二甲基苯并噁唑酮(DMXAA)激活cGAS-STING通路显著降低了BJOE的治疗、抗炎及屏障保护作用。同样,刺激STING可显著逆转BJOE对cGAS-STING通路的抑制作用。
结论
BJOE至少部分通过抑制伊立替康诱导的迟发性腹泻中的cGAS-STING通路,有效减轻炎症并维持肠道屏障功能。有必要进行活性成分、长期安全性及药代动力学研究以促进其转化应用。